$NRSN Glad to share that NeuroSense Therapeutics has been granted a new U.S. patent covering the use of our novel platform in Alzheimer’s disease, extending protection through 2043. A meaningful IP milestone supporting long-term development and commercialization. 👉

$NRSN Off on a 2-week business trip to NYC, Boston & CA 🇺🇸✈️ Busy schedule, but might squeeze in a meeting or two - feel free to ping me if you’re around. I’ll be sharing updates along the way on Instagram: 👉 instagram.com/alonbennoon

NeuroSense reports that its Phase 2 proof-of-concept study of PrimeC in Alzheimer’s disease confirmed its primary endpoint of safety and tolerability; Additional clinical and biomarker analyses expected in Q1 2026. $NRSN #Alzheimers #Biotech prnewswire.com/news-releases…

Heading to Southern California for a conference and several key meetings. I’ve left time open to connect with founders, researchers, clinicians, and investors working in ALS and neuroscience. DM me if you’d like to meet. #ALS #California $NRSN

From PARADIGM to PARAGON: On October 10 at NEALS 2025, Prof. Merit Cudkowicz will unveil the design of our global Phase 3 PARAGON trial of PrimeC in ALS. Built on insights from our Phase 2b PARADIGM study, PARAGON is designed to rigorously confirm PrimeC’s potential to preserve function and change disease trajectory. PrimeC - NeuroSense’s lead candidate, is a patented, extended-release oral formulation: a unique fixed-dose combination of two FDA-approved drugs that targets multiple ALS-relevant pathways. In PARADIGM PrimeC was well tolerated and over 18 months, reduced functional decline by 32.8% (p=0.007), improved bulbar function, favorably modulated key biomarkers and significantly improved ALS complication-free survival at 18 months (p=0.02). If you’re at NEALS, join us for the talk, and our poster, “From PARADIGM to PARAGON.” #NEALS2025 #ALS #PrimeC $NRSN

Another step forward for PrimeC. Today we shared new biomarker findings from our PARADIGM study, showing that PrimeC significantly reduced several key microRNAs linked to Alzheimer’s disease biology - pathways related to neuroinflammation, amyloid and tau. While this reinforces PrimeC’s multi-target mechanism, our main focus remains clear: advancing our Phase 3 program in ALS and bringing this therapy to the people who need it most. There’s nothing standing in our way - science, determination, and purpose continue to guide us. $NRSN #PrimeC #ALS #Alzheimers #Neurodegeneration

Do You Remember? 💜 $NRSN for Alzheimer’s youtu.be/1v57o9qBqrM?si=FL8l… via @YouTube

You are more than welcome to submit your questions before or during the live event. 🙂 $NRSN

$NRSN A lot is going on at NeuroSense Therapeutics. Here are some updates of what we did in the second quarter of this year. Watch here 👇 youtu.be/bo4ZNja0Pqc?si=Keb-…

Full steam ahead! We're ramping up manufacturing with our partners at Recipharm to ensure we're ready for market. Looking forward to big updates very soon. Stay tuned! $NRSN

$NRSN Got a few questions today about whether we're planning a private placement. 🤨 The plain answer: No. Now's not the time. We believe there are better options ahead for the company - and we're focused on those.

$NRSN Good news, and more to come. finance.yahoo.com/news/neuro…

I’m the Luckiest Man on Earth. This ALS Awareness Month, we honor the strength of patients & families - and keep pushing forward. At @NeuroSenseTX, every step we take is for them - and yes, we’re on the right path, on all fronts. #ALSAwarenessMonth #ALS #Hope #PrimeC $NRSN linkedin.com/posts/alonbn_th…

$NRSN Today I shared a letter to shareholders providing an overview and updates on how we're advancing on multiple fronts, including Phase 3 preparations for PrimeC in ALS, Canadian regulatory pathway progress, our recent clinical validation, and our ongoing partnership discussions with a leading global pharmaceutical company. We remain optimistic about these ongoing talks that we believe have the potential to bring forth a truly transformative result for our company and ALS patients. I also want to take this opportunity to thank our shareholders and stakeholders for their continued support and confidence. Our entire team is working very hard and we are committed to creating value for our investors bringing hope to those suffering from this debilitating disease. prnewswire.com/news-releases…

$NRSN – Initial updates: Making progress on all fronts. Catch PrimeC featured on @i24NEWS_EN yesterday - advancing hope in ALS. #ALS #PrimeC #NeuroSense #biotech youtu.be/i84GorK0ZDU?si=Msdy…

Today around 1:40pm est, on TV @i24NEWS_EN : I’ll be sharing our journey developing a promising therapy for ALS. From what we’ve achieved with PrimeC to where we’re headed next - hope is in motion. 🌍🧠 #ALS #biotech #PrimeC #NeuroSense $NRSN i24news.tv/en